Triple Analysis: Decoding Big Pharma's R&D Strategy in Oncology and Special Focus Lung Cancer and Melanoma

Published by: BioSeeker Group AB

Published: Sep. 14, 2007 - 510+ Pages

Table of Contents

1 Executive Summary

2 Methodologies

3 Table of Contents

3.1 List of Tables

3.2 List of Boxes

4 Big Pharma’s R&D Position and Strategy in Oncology: A Summary

4.1 Bristol-Myers Squibb

4.2 GlaxoSmithKline

4.3 Hoffmann-La Roche

4.4 Novartis

4.5 Sanofi-Aventis

5 Last Five Years of Deals and Alliances in Oncology

5.1 Bristol Myers Squibb

5.1.1 Discovery and Lead Molecule Improvements

5.1.2 Adding Image Analysis to Support Clinical Trials and Early Diagnosis

5.1.3 Bladder Cancer and Melanoma Registration Filings are Emminent

5.1.4 The Human Kinome and Cell Cycle Inhibitors

5.1.5 Strategic Priorities in Pipeline Development Leads to Divestments

5.1.6 Erbitux Expansion is Set to Challenge Avastin

5.2 GlaxoSmithKline

5.2.1 The Biopharmaceutical Strategy at GSK

5.2.2 Out Goes Classes of Small Molecule Inhibitors

5.2.3 Marketing and Manufacturing Collaborations

5.2.4 Patient Selectionfo r GSK’s Targeted Cancer Therapies

5.2.5 GSK Taping Into Knowledge Databases

5.2.6 Increasing the Oral Bioavailability Cytotoxic Oncology Drugs

5.2.7 Oxford University Helps GSK in India

5.2.8 GSK is Set to Improve Medical Imaging

5.3 Hoffmann-La Roche

5.3.1 Roche Builds Center of Excellence for RNAi Therapeutics Discovery

5.3.2 A New Delivery Route for Avastin?

5.3.3 Improving Antibody Drugs

5.3.4 Roche Strengthens Presence in Genomics Research Market

5.3.5 Target Validation

5.3.6 Drug Discovery Collaborations

5.3.7 Marketing

5.3.8 Outlicensing

5.3.9 Size Doesn’t Matter: Genentech's Goal of Aggressively Pursuing Novel and Innovative Therapies 71

5.4 Novartis

5.4.1 Novartis Acquisition of Chiron: A Major Biopharmaceutical Investment

5.4.2 Protein Kinase Inhibitors

5.4.3 Next Generation Oral Topoisomerase Inhibitor and Telomerase Promotors

5.4.4 Novartis Sells of World-Wide Rights

5.4.5 Biomarker and Proteomics Research

5.5 Sanofi-Aventis

5.5.1 Target Screening and Validation

5.5.2 Biologicals

5.5.3 A Short Cut to Success?

5.5.4 Aventis Divests Interest

5.5.5 Recombine My Molecule

6 Competitive R&D Comparison on Oncology Drug Target Level

6.1 Target Overview

6.2 Head to Head Target Comparison by Molecular Function and Cancer Type

6.2.1 Transmembrane Receptor Protein Tyrosine Kinase Activity Targets

6.2.2 Receptor Activity Targets

6.2.3 G-protein Coupled Receptor Activity Targets

6.2.4 Protein Serine/Threonine Kinase Activity Targets

6.2.5 Transcription Factor Activity Targets

6.2.6 Transmembrane Receptor Activity Targets

6.2.7 Catalytic Activity Targets

6.2.8 Cytokine Activity Targets

6.2.9 Protein-Tyrosine Kinase Activity Targets

6.2.10 Kinase Activity Targets

6.2.11 DNA Topoisomerase Activity Targets

6.2.12 Growth Factor Activity Targets

6.2.13 Ligase Activity Targets

6.2.14 Motor Activity Targets

6.2.15 Structural Constituent of Cytoskeleton Targets

6.2.16 Transporter Activity Targets

6.2.17 Targets According to Miscellaneous Molecular Function Groups

6.2.18 Unclassified or Unknown Molecular Function of Targets

6.3 Drug Targets by Target Localization and Compound Type

6.4 Targets, Drugs and Cancer Indications Linked to Signaling Pathways

6.4.1 Alpha6 Beta4 Integrin Signaling Pathway

6.4.2 Androgen Receptor Signaling Pathway

6.4.3 B Cell Receptor Signaling Pathway

6.4.4 EGFR1 Signaling Pathway

6.4.5 Hedgehog Signaling Pathway

6.4.6 ID Signaling Pathway

6.4.7 IL-1 Signaling Pathway

6.4.8 IL-2 Signaling Pathway

6.4.9 IL-3 Signaling Pathway

6.4.10 IL-4 Signaling Pathway

6.4.11 IL-5 Signaling Pathway

6.4.12 IL-6 Signaling Pathway

6.4.13 IL-9 Signaling Pathway

6.4.14 Kit Receptor Signaling Pathway

6.4.15 Notch Signaling Pathway

6.4.16 T Cell Receptor Signaling Pathway

6.4.17 TGF-beta Receptor Signaling Pathway

6.4.18 TNF-alpha Signaling Pathway

6.4.19 Wnt Signaling Pathway

7 Drug Compound Type Analysis

7.1 Deployment of Biological Based Compounds by Cancer Indications

7.2 Deployment of Chemical Based Compounds by Cancer Indications

7.3 Deployment of Natural Product Compounds by Cancer Indications

8 Drug Development in Oncology by Major Targeted Therapy Areas

8.1 Angiogenesis

8.2 Antibodies

8.3 Apoptosis

8.4 Protein Kinase Inhibitors

8.5 Vaccines

9 Cancer Indication Focus Analysis

9.1 Preclinical Stage Pipeline

9.2 Phase I Clinical Stage Pipeline

9.3 Phase II Clinical Stage Pipeline

9.4 Phase III Clinical Stage Pipeline

9.5 Drugs Soon to be on the Market

9.6 Approved Drugs

10 Lung cancer: An Introduction

10.1 Current Treatment Strategies

10.2 Disease Definition

10.3 Etiology & Pathophysiology

10.4 Prognosis

10.5 Epidemiology

11 Progress in Current Lung Cancer Treatment Strategies

11.1 Improvements Adding microtubule Inhibitor

11.2 Improvement of Disease Related Symptoms in Elderly Patients

11.3 Toxicity Profile Favored

11.4 A New Formula

11.5 Monotherapy?

11.6 Failed to Demonstrate a Survival Advantage

11.7 Reduction in Mortality Risk

12 Key Drug Strategies in Lung Cancer

12.1 Apoptosis

12.2 Antiangiogenesis and Antivascular Agents

12.2.1 EGFR and VEGFR as target

12.2.2 Immunotherapy

13 Competitive Landscape in Lung Cancer Drug Development: The Late Stage Pipeline

13.1 Grade 4 Adverse Events

13.2 No New Remarks

13.3 No Significant Effect on Overall Survival

13.4 Bristol Myers Squibb Entered into an Agreement

13.5 Many Uncertainties Remain

13.6 Development Terminated

13.7 Continuing Enrollment

13.8 Apoptotic Inducer

13.9 Fully-Human Monoclonal Antibody

13.10 Eagerly Awaiting Data

13.11 Mutations and Response

13.12 Statistically and Clinically Significant Survival Advantage

13.13 Anti-Idiotypic Monoclonal Antibody

13.14 Shift in the Development Focus

13.15 Sensitizer

13.16 Treatment in Earlier-Stage Cancer Could be More Effective

13.17 Discontinued Radiosensitizer

13.18 Improvement in Chemoradiotherapy

13.19 Progress on HDAC Inhibitor

13.20 Progress Analysis Carboxyamidotriazole

13.21

13.22 Chemotherapy naïve subjects

14 Etiology and Pathophysiology of Melanoma

15 Current Melanoma Treatment Strategies

15.1 An Overview

15.2 Cytotoxic Drugs

15.2.1 Dacarbazine

15.2.2 Cisplatin

15.2.3 Carboplatin

15.2.4 Carmustine

15.2.5 Melphalan

15.2.6 Paclitaxel

15.2.7 Tamoxifen

15.2.8 Temozolomide

15.2.9 Vinblastine/Vinorelbine

15.3 Biological treatments

15.3.1 Intron A

15.3.2 Virulizin

15.3.3 Melacine

15.3.4 Alfanative (Multiferon)

15.3.5 Proleukin or (Macrolin)

15.3.6 Enhanzyn

15.3.7 M-VAX

15.4 Other

15.4.1 Ceplene Maxamine

16 Key Melanoma Therapy Strategies

16.1 Immunotherapy

16.2 Anti-angiogenesis

16.3 Apoptotic Induction

16.4 Gene Therapy

17 Current Melanoma Drug Development: Late Stage Pipeline

17.1 Immunotherapy

17.1.1 Oncophage

17.1.2 Canvaxin

17.1.3 GMK

17.1.4 MDX-010

17.1.5 OncoVax

17.1.6 ALLOVECTIN-7

17.1.7 Peginterferon alfa-2b

17.2 Anti-angiogenesis

17.2.1 Lenalidomide

17.3 Apoptotic Inducers

17.3.1 Genasense

17.4 Inhibiting Cell Growth

17.4.1 Temozolomide

18 Current Melanoma Drug Development: Early Stage Pipeline

18.1 Immunotherapy

18.1.1 INGN 241

18.1.2 QS-21

18.1.3 Talabostat

18.1.4 SB 249553

18.1.5 GVAX

18.1.6 GV 1001

18.1.7 Dexosome

18.1.8 Uvidem

18.1.9 NY-ESO-1 ISCOMS

18.1.10 NOVOVAC-M1

18.1.11 Oxxon Vaccine

18.1.12 Therion’s Melanoma Vaccine

18.1.13 ImmunoVex trimelan

18.1.14 OncoVEXGM-CSF

18.1.15 Zadaxin

18.1.16 Alvac-Mage1/Mage3

18.1.17 Iboctadekin

18.1.18 ProMune

18.1.19 BAY 504798

18.1.20 EMD 273063

18.2 Antiangiogenesis

18.2.1 Sorafenib

18.2.2 Vitaxin

18.2.3 Avastin

18.2.4 PI 88

18.3 Apoptotic Inducers

18.3.1 Didemnin B

18.3.2 KOS 953

18.4 Small Molecules Inhibiting Cell Growth

18.4.1 Pivanex

18.4.2 Karenitecin

18.4.3 Lomeguatrib

18.4.4 PD 0325901

18.4.5 SB 715992

18.4.6 INO 1001

18.4.7 CP 4055

18.5 Other Biological Drugs

18.5.1 AP 12009

18.5.2 Ecromeximab

18.5.3 ILX 651

18.5.4 Kahalalide F

18.5.5 ABX MA1

18.5.6 MJV 101

18.5.7 A Russian Melanoma Vaccine

18.5.8 Elea Vaccine

18.5.9 F 50040

19 Appendix 1. Treatment Guide Lines Lung Cancer*

19.1 References

20 Appendix 2: Selected Company Profiles

20.1 Abgenix

20.2 Aphton

20.3 AstraZeneca

20.4 Bristol-Myers Squibb

20.5 Eli Lilly

20.6 Genentech

20.7 Genta

20.8 GlaxoSmithKline

20.9 ImClone

20.10 ISIS Pharmaceuticals

20.11 Ligand Pharmaceuticals

20.12 OSI Pharmaceuticals

20.13 Pfizer

20.14 Pharmacyclics

20.15 Sanofi- Aventis

20.16 Telik

21 Appendix 3 Progress profiles on approved drugs

21.1 Docetaxel

21.2 Vinorelbine

21.3 Gemcitabine

21.4 Paclitaxel

21.5 Pemetrexed

21.6 Gefitinib

21.7 Erlotinib

22 Appendix 4: Treatment Guide Lines Melanoma

23 Disclaimer

24 Drug Index

25 Company Index

List of Tables

Table 1: How to Navigate the Report

Table 2: Number of Pursued Oncology Drugs Targets by Company

Table 3: Pursued Oncology Drugs Targets by Molecular Function

Table 4: Drug Target Expression Profiles in Humans

Table 5: Identified Targets By Cancer Indications

Table 6: Head to Head Comparison of Drugs with Transmembrane Receptor Protein Tyrosine Kinase Activity Targets

Table 7: Head to Head Comparison of Drugs with Receptor Activity Targets

Table 8: Head to Head Comparison of Drugs with G-protein Coupled Receptor Activity

Table 9: Head to Head Comparison of Drugs with Protein Serine/Threonine Kinase Activity

Table 10: Head to Head Comparison of Drugs with Transcription Factor Activity Targets

Table 11: Head to Head Comparison of Drugs with Transmembrane Receptor Activity Targets

Table 12: Head to Head Comparison of Drugs with Catalytic Activity Targets

Table 13: Head to Head Comparison of Drugs with Cytokine Activity Targets

Table 14: Head to Head Comparison of Drugs with Protein-Tyrosine Kinase Activity Targets

Table 15: Head to Head Comparison of Drugs with Kinase Activity Targets

Table 16: Head to Head Comparison of Drugs with DNA Topoisomerase Activity Targets

Table 17: Head to Head Comparison of Drugs with Growth Factor Activity Targets

Table 18: Head to Head Comparison of Drugs with Ligase Activity Targets

Table 19: Head to Head Comparison of Drugs with Motor Activity Targets

Table 20: Head to Head Comparison of Drugs with Structural Constituent of Cytoskeleton Targets

Table 21: Head to Head Comparison of Drugs with Transporter Activity Targets

Table 22: Head to Head Comparison of Drugs with Targets According to Miscellaneous Molecular Function Groups

Table 23: Head to Head Comparison of Drugs with Unclassified or Unknown Molecular Function Targets

Table 24: Drug Target Comparison by Target Localization and Compound Type

Table 25: Targeting Signaling Pathways: An Overview

Table 26: Targeted Signaling Pathway Profiles of Big Pharma

Table 27: Targets, Drugs and Cancer Indications Linked to the Alpha6 Beta4 Integrin Signaling Pathway

Table 28: Targets, Drugs and Cancer Indications Linked to the Androgen Receptor Signaling Pathway

Table 29: Targets, Drugs and Cancer Indications Linked to the B Cell Receptor Signaling Pathway

Table 30: Targets, Drugs and Cancer Indications Linked to the EGFR1 Signaling Pathway

Table 31: Targets, Drugs and Cancer Indications Linked to the Hedgehog Signaling Pathway

Table 32: Targets, Drugs and Cancer Indications Linked to the ID Signaling Pathway

Table 33: Targets, Drugs and Cancer Indications Linked to the IL-1 Signaling Pathway

Table 34: Targets, Drugs and Cancer Indications Linked to the IL-3 Signaling Pathway

Table 35: Targets, Drugs and Cancer Indications Linked to the IL-4 Signaling Pathway

Table 36: Targets, Drugs and Cancer Indications Linked to the IL-5 Signaling Pathway

Table 37: Targets, Drugs and Cancer Indications Linked to the IL-6 Signaling Pathway

Table 38: Targets, Drugs and Cancer Indications Linked to the Kit Receptor Signaling Pathway

Table 39: Targets, Drugs and Cancer Indications Linked to the Notch Signaling Pathway

Table 40: Targets, Drugs and Cancer Indications Linked to the T Cell Receptor Signaling Pathway

Table 41: Targets, Drugs and Cancer Indications Linked to the TGF-beta Receptor Signaling Pathway

Table 42: Targets, Drugs and Cancer Indications Linked to the TNF-alpha Signaling Pathway

Table 43: Targets, Drugs and Cancer Indications Linked to the Wnt Signaling Pathway

Table 44: Deployment of Biological Based Compounds by Cancer Indications

Table 45: Deployment of Chemical Based Compounds by Cancer Indications

Table 46: Deployment of Natural Product Based Compounds by Cancer Indications

Table 47: Comparative Presentation of Targeted Therapy Areas in Oncology

Table 48: The Angiogenesis Pipeline by Cancer Type and Developmental Stage

Table 49: The Antibody Pipeline by Cancer Type and Developmental Stage

Table 50: The Apoptosis Pipeline by Cancer Type and Developmental Stage

Table 51: The Protein Kinase Inhibitor Pipeline by Cancer Type and Developmental Stage

Table 52: The Cancer Vaccine Pipeline by Cancer Type and Developmental Stage

Table 53: Summary of Big Pharma’s Preclinical Stage Pipeline

Table 54: Preclinical Stage Pipeline by Cancer Indications

Table 55: Summary of Big Pharma’s Phase I Clinical Stage Pipeline

Table 56: : Phase I Clinical Stage Pipeline by Cancer Indications

Table 57: Summary of Big Pharma’s Phase II Clinical Stage Pipeline

Table 58: Phase II Clinical Stage Pipeline by Cancer Indications

Table 59: Summary of Big Pharma’s Phase III Clinical Stage Pipeline

Table 60: Phase III Clinical Stage Pipeline by Cancer Indications

Table 61: Oncology Drugs Soon to be on the Market

Table 62: Summary of Big Pharma’s Approved Oncology Drugs

Table 63: Approved Drugs by Cancer Indications

Table 64: Chemotherapeutic drugs for treatment of NSCLC

Table 65. Near Term Approved Drugs for the Treatment of NSCLC

Table 66: Chemotherapy Drugs off Patent

Table 67 Generalized Illustration, Depicting the Key Elements Involved in the Apoptotic Pathways. . 271

Table 68 VTA agents under development

Table 69 EGFR or VEGFR inhibitors

Table 70: FMS-like tyrosine kinases and their Synonyms

Table 71: Fms-related Tyrosine Kinase Targets in Development

Table 72: Protein Kinase Targets in Clinical Trials for Lung Cancer

Table 73 Cancer immunotherapy strategies

Table 74 Recently presented studies Lapatinib

Table 75 Recently presented studies ZD-6474

Table 76 Recently presented studies vinflunine

Table 77 Recently presented studies Panitumumab

Table 78 Recently presented studies Genasense

Table 79 Recently presented studies cetuximab

Table 80 Recently presented studies bevacizumab

Table 81 Recently presented studies bexarotene

Table 82 Recently presented studies Xcytrin

Table 83: Critical Risk Factors for Development of Melanoma

Table 84: Definition and Description of Stages of Melanoma

Table 85: Prognosis of the 4 Stages of Malignant Melanoma

Table 86: Current Cytotoxic Drugs for the Treatment of Melanoma

Table 87: Progress Profile Dacarbazine

Table 88: Progress Profile Cisplatin

Table 89: Progress Profile Carboplatin

Table 90: Progress Profile Carmustine

Table 91: Progress Profile Melphalan

Table 92: Progress Profile Paclitaxel

Table 93: Progress Profile Tamoxifen

Table 94: Progress Profile Temozolomide

Table 95: Progress Profile Vinblastine/Vinorelbine

Table 96: Progress Profile Interferon alfa-2b

Table 97: Development Milestones- Virulizin

Table 98: Development Milestones - Melacine

Table 99: Development Milestones - Alfanative

Table 100: Development Milestones - Proleukin

Table 101: Deployed Strategies for Blocking Angiogenesis

Table 102: Phase III Randomized Studies of Melanoma Vaccines.

Table 103: Tumor antigen based vaccines

Table 104: In vivo Gene Therapy

Table 105: Cell Therapy Based Platform in Pipeline as Potential Treatment of Melanoma

Table 106: Ex vivo gene therapy loading of antigen presenting cells

Table 107: Overview of Immunostimulants in Development based on Type

Table 108: Overview of Immuno-Biologicals

Table 109: Overview of Gene Therapy Drugs for Immunostimulation

Table 110: MDX-010’s Collaborative History and Landscape

Table 111: Anti-angiogenisis Drugs under Development

Table 112: Overview Apoptopic Inducer Drugs

Table 113: Overview of Small Molecule Drugs

Table 114:Selected Regulatory Progress of Sorafenib

Table 115: Selected Regulatory Progress of Didemin B

Table 116: Overview of Various Biological Drugs in Development for Melanoma

List of Boxes

Box 1: Quick facts on Docetaxel

Box 2: Scientific Data on Docetaxel

Box 3: Quick Facts - Vinorelbine

Box 4: Scientific Data on Vinorelbine

Box 5: Quick Facts - Gemcitabine

Box 6: Scientific Data on gemcitabine

Box 7: Quick Facts - pemetrexed

Box 8: Scientific Data on Pemetrexed

Box 9: Quick Facts - Gefitinib

Box 10: Scientific Data on Gefitinib

Box 11: Quick Facts - Erlotinib

Box 12: Quick Facts - Enhanzyn

Box 13: Quick Facts - M-VAX

Box 14: M-VAX - Business & Market Bakground

Box 15: Mechanisms which Tumor Cells use to Evade an Immune Reaction

Box 16: Introgen’s INGN 241 Shows Vaccine Properties

Box 17: Quick Facts - Oncophage

Box 18: Oncophage - Designation and Status

Box 19: Quick Facts - Canvaxin

Box 20: Canvaxin - Designation and Status

Box 21: CancerVax Milestone payment

Box 22: Quick Facts - GM2-KLH Vaccine

Box 23: Progenics Reaquires Rights to Vaccine

Box 24: Completed Melanoma Phase III trials

Box 25: Quick Facts - MDX-010

Box 26: Quick Facts -OncoVax

Box 27: Quick Facts - ALLOVECTIN-7

Box 28: Quick Facts - Peginterferon alfa-2b

Box 29: Introgen’s INGN 241 Shows Anti-angiogenesis Properties

Box 30: Quick Facts - Lenalidomide

Box 31: Quick Facts - Oblimersen

Box 32: Quick Facts - Temozomide

Box 33: Molecular Pathways Underlying the Activity of Temozolomide’s Anti-Cancer Therapy

Box 34: Regulatory Progress

Box 35: Quick Facts - INGN 241

Box 36: Molecular Pathways Underlying Activity of Introgen's INGN 241 Anti-Cancer Therapy

Box 37: Quick Facts - QS-21

Box 38: Quick Facts - Talabostat

Box 39: Quick Facts - SB 249553

Box 40: Quick Facts - GVAX

Box 41: Agreement Japan Tobacco and Cell Genesys

Box 42: Predicted launch of GVAX

Box 43: Quick Facts - GV 1001

Box 44: Quick Facts - Dexosome

Box 45: Important Milestones and License Fees

Box 46: Quick Facts - Uvidem

Box 47: Agreements Between Sanofi-Aventis and IDM

Box 48: Quick Facts - NY-ESO-1 ISCOMS

Box 49: NY-ESO-1 and ISCOMATRIX

Box 50: Quick Facts - NovoVac-M1

Box 51: Quick Facts - Oxxon vaccine

Box 52: Quick Facts - Therion’s Melanoma Vaccine

Box 53: Quick Facts - ImmunoVEX trimelan

Box 54: Quick Facts - OncoVEX GM-CSF

Box 55: Quick Facts - ZADAXIN

Box 56: Developmental History Thymosin alpha1

Box 57: Quick Facts - Alvac-Mage1/Mage3

Box 58: Quick Facts - iboctadekin

Box 59: Quick Facts - PF-3512676

Box 60: Quick Facts - BAY-504798

Box 61: Quick Facts - EMD-273063

Box 62: Quick Facts - Sorefenib

Box 63: Quick Facts - Vitaxin

Box 64: Quick Facts . Bevacizumab

Box 65: Quick Facts - PI88

Box 66: Quick Facts - Didemnin B

Box 67: Quick Facts - KOS 953

Box 68: Quick Facts - Pivanex

Box 69: Quick Facts - Karenitecin

Box 70: Company Statement

Box 71: Quick Facts - Lomeguatrib

Box 72: Quick Facts - PD 0325901

Box 73: Quick Facts - SB 715992

Box 74: Quick Facts - INO 1001

Box 75: Quick Facts - CP 4055

Box 76: Quick Facts - AP 12009

Box 77: Quick Facts - Ecromeximab

Box 78: Quick Facts - ILX 651

Box 79: Quick Facts - Kahalalide F

Box 80: Quick Facts - ABX MA1

Box 81: Quick Facts - MJV 101

Box 82: Quick Facts - Russian Melanoma Vaccine

Box 83: Quick Facts - N-Acetyl-GM3 ganglioside

Box 84: Quick Facts - F 50040

Box 85: KpOmpA Technology

Abstract

Executive Summary

This is the report for professionals interested to grasp big pharma’s R&D strategy in oncology and at the same time have an extensive R&D overview of the lung cancer and melanoma field. This extensive 510+ pages report compiles and analyzes Deals and alliances, Drug targets, Compound types, Targeted therapy areas, and Selection of cancer indications among the five major pharmaceutical companies in the oncology arena: Bristol-Myers Squibb, GlaxoSmithKline, Hoffmann-La Roche, and Sanofi-Aventis. Between them and together with their respective partners they have more than 250 drugs for the treatment of cancer. In other words, their collective R&D capacity and presence is solid enough to set trends for the entire field of oncology drug development. Beyond trends, all five are fiercely defining their competitive edge and advantage in oncology and that is what this report is about.

The collective force of the above research and analysis ’decodes’ these five big pharma R&D efforts into strategy revealing and gap filing presentations. Enough to fuel and sustain comparative benchmarking, peer group surveillance, and partnership decisions.

The report further give an in depth analysis in two important key oncology areas; Lung- and Melanoma cancer. And provide a framework but also a careful identification and evaluation of drug candidates, technologies and competitors.

Decoding Big Pharma’s R&D Strategy in Oncology in numbers:

• Includes references to more than 250 drugs and 600 clinical/preclinical trials
• Addresses the competitive situation on more than 80 different cancer indications, including supportive care indications
• Special focus on Angiogenesis-, Antibody-, Apoptosis-, Protein kinase inhibitor- and Vaccine drugs for the treatment of cancer
• The included competitive landscape between the five big pharma includes more than 200 companies related to cancer drug development
• Last five years of deals and alliances in oncology, including almost a hundred different key deals and alliances
• Target analysis of 119 drug targets in oncology, including molecular function of target, target localization, type of compound for targeting, targets affecting signaling pathways etc
• Drug compound analysis by cancer indications

The risk of malignant melanoma has more than doubled in the past decade. The incidence of melanoma is rising faster than that of any other cancer. This in-depth analysis of the progress of melanoma R&D and current treatment strategies is one of the most extensive reports available in this field. No less than 68 approved drugs and drug candidates have been studied. Progress profiles and structured information will allow you to pin-point your knowledge-base in a most cost-effective way. New interesting phase III studies have been initiated. By gathering information around most drugs under development for melanoma and specially the late stage pipeline it has been clear that four major therapeutic strategies generated the most interesting data.

Lung cancer is the third most common malignant disease and the first leading cause of cancer death in the western world. Yet platinum agent constitutes the current mainstay of front-line metastatic lung cancer treatment. There are currently two platinum-based compounds that are marketed and clinically used worldwide as treatment for NSCLC: cisplatin and carboplatin. These two drugs are combined with paclitaxel, docetaxel, gemcitabine or vinorelbine to build the first-line treatment options. Several different studies have been comparing or are comparing differ combinations of these drugs. Lately gefitinib, pemetrexed and erlotinib have entered the market and are initially used in second or third-line treatments. In this report we are not only describing the progress of different combinations of approved drugs but as well the progress of 21 late stage drug candidates are described and analyzed. Progress profiles and structured information will allow you to pin-point your knowledge-base in a most cost-effective way. By gathering information around most drugs under development for lung cancer and specially the late stage pipeline it is has been clear that four major therapeutic strategies generated most interesting data. With this report you will be able to track down and foresee activities associated with the development of new treatments for lung cancer. According to market analytical studies, the NSCLC drug market is predicted to exceed $4 billion between 2010 and 2015. Chemotherapy drugs will experience generic erosion and three major chemotherapy drugs go off patent before 2012; Aventis’ Taxotere (docetaxel), Bristol-Myers Squibb’s Paraplatin (carboplatin) and Eli Lilly’s Gemzar (gemcitabine).

Get Full Details About This Report >>

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 160,000 market research reports, company profiles and country profiles from over 600 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.